-
公开(公告)号：US20060100155A1
公开(公告)日：2006-05-11
申请号：US11311363
申请日：2005-12-20
申请人： Hilde Riethmuller-Winzen , Jurgen Engel , Ricardo Felberbaum , Klaus Diedrich , Wolfgang Kupker
发明人： Hilde Riethmuller-Winzen , Jurgen Engel , Ricardo Felberbaum , Klaus Diedrich , Wolfgang Kupker
CPC分类号： A61K38/08 , A61K45/06 , A61K2300/00
摘要： The present inventions provides a method for therapeutic management of extrauterine proliferation of endometrial tissue, chronic pelvic pain and fallopian tube obstruction by short term induction treatment with an LH-RH antagonist for 4 to 12 weeks. According to another aspect of the present invention, the short term LH-RH treatment is followed by the combined or separate administration of one or more active agents selected from the group consisting of a contraceptive, preferably an oral contraceptive, a non-steroidal anti-rheumatic agent, an analgetic, an androgen other than a 17-alpha-alkyl substituted testosterone or any combinations thereof. According to a further aspect of the present invention a pharmaceutical composition comprising an LHRH antagonist and one ore more active agents selected from the group consisting of a contraceptive, preferably an oral contraceptive, a non-steroidal anti-rheumatic agent, an analgetic, an androgen other than a 17-alpha-alkyl substituted testosterone or any combinations thereof are provided.
摘要翻译： 本发明提供了一种通过LH-RH拮抗剂短期诱导治疗4至12周来治疗子宫内膜组织宫外增生，慢性盆腔疼痛和输卵管阻塞的方法。 根据本发明的另一方面，短期LH-RH治疗之后是联合或分开施用一种或多种活性剂，所述活性剂选自避孕药，优选口服避孕药，非类固醇抗生素， 风湿药，止痛剂，除17-α-烷基取代的睾酮以外的雄激素或其任何组合。 根据本发明的另一方面，包含LHRH拮抗剂和一种或多种选自避孕药，优选口服避孕药，非甾体抗风湿药，止痛剂，雄激素的活性剂的药物组合物 提供除17-α-烷基取代的睾酮或其任何组合以外的物质。
-
公开(公告)号：US07666836B2
公开(公告)日：2010-02-23
申请号：US11311363
申请日：2005-12-20
申请人： Hilde Riethmuller-Winzen , Jurgen Engel , Ricardo Felberbaum , Klaus Diedrich , Kupker Wolfgang
发明人： Hilde Riethmuller-Winzen , Jurgen Engel , Ricardo Felberbaum , Klaus Diedrich , Kupker Wolfgang
IPC分类号： A61K38/00 , A61K31/497 , A61K31/519 , A61K31/505
CPC分类号： A61K38/08 , A61K45/06 , A61K2300/00
摘要： The present inventions provides a method for therapeutic management of extrauterine proliferation of endometrial tissue, chronic pelvic pain and fallopian tube obstruction by short term induction treatment with an LH-RH antagonist for 4 to 12 weeks. According to another aspect of the present invention, the short term LH-RH treatment is followed by the combined or separate administration of one or more active agents selected from the group consisting of a contraceptive, preferably an oral contraceptive, a non-steroidal anti-rheumatic agent, an analgetic, an androgen other than a 17-alpha-alkyl substituted testosterone or any combinations thereof. According to a further aspect of the present invention a pharmaceutical composition comprising an LHRH antagonist and one ore more active agents selected from the group consisting of a contraceptive, preferably an oral contraceptive, a non-steroidal anti-rheumatic agent, an analgetic, an androgen other than a 17-alpha-alkyl substituted testosterone or any combinations thereof are provided.
摘要翻译： 本发明提供了一种通过LH-RH拮抗剂短期诱导治疗4至12周来治疗子宫内膜组织宫外增生，慢性盆腔疼痛和输卵管阻塞的方法。 根据本发明的另一方面，短期LH-RH治疗之后是联合或分开施用一种或多种活性剂，所述活性剂选自避孕药，优选口服避孕药，非类固醇抗生素， 风湿药，止痛剂，除17-α-烷基取代的睾酮以外的雄激素或其任何组合。 根据本发明的另一方面，包含LHRH拮抗剂和一种或多种选自避孕药，优选口服避孕药，非甾体抗风湿药，止痛剂，雄激素的活性剂的药物组合物 提供除17-α-烷基取代的睾酮或其任何组合以外的物质。
-
公开(公告)号：US20080255053A1
公开(公告)日：2008-10-16
申请号：US12099091
申请日：2008-04-07
申请人： Hilde RIETHMULLER-WINZEN , Jurgen Engel , Ricardo Felberbaum , Klaus Diedrich , Kupker Wolfgang
发明人： Hilde RIETHMULLER-WINZEN , Jurgen Engel , Ricardo Felberbaum , Klaus Diedrich , Kupker Wolfgang
IPC分类号： A61K38/08
CPC分类号： A61K38/08 , A61K45/06 , A61K2300/00
摘要： The present inventions provides a method for therapeutic management of extrauterine proliferation of endometrial tissue, chronic pelvic pain and fallopian tube obstruction by short term induction treatment with an LH-RH antagonist for 4 to 12 weeks. According to another aspect of the present invention, the short term LH-RH treatment is followed by the combined or separate administration of one or more active agents selected from the group consisting of a contraceptive, preferably an oral contraceptive, a non-steroidal anti-rheumatic agent, an analgetic, an androgen other than a 17-alpha-alkyl substituted testosterone or any combinations thereof. According to a further aspect of the present invention a pharmaceutical composition comprising an LHRH antagonist and one ore more active agents selected from the group consisting of a contraceptive, preferably an oral contraceptive, a non-steroidal anti-rheumatic agent, an analgetic, an androgen other than a 17-alpha-alkyl substituted testosterone or any combinations thereof are provided.
摘要翻译： 本发明提供了一种通过LH-RH拮抗剂短期诱导治疗4至12周来治疗子宫内膜组织宫外增生，慢性盆腔疼痛和输卵管阻塞的方法。 根据本发明的另一方面，短期LH-RH治疗之后是联合或分开施用一种或多种活性剂，所述活性剂选自避孕药，优选口服避孕药，非类固醇抗生素， 风湿药，止痛剂，除17-α-烷基取代的睾酮以外的雄激素或其任何组合。 根据本发明的另一方面，包含LHRH拮抗剂和一种或多种选自避孕药，优选口服避孕药，非甾体抗风湿药，止痛剂，雄激素的活性剂的药物组合物 提供除17-α-烷基取代的睾酮或其任何组合以外的物质。
-
4.发明授权公开(公告)号：US07005418B1
公开(公告)日：2006-02-28
申请号：US09666146
申请日：2000-09-20
申请人： Hilde Riethmuller-Winzen , Jurgen Engel , Ricardo Felberbaum , Klaus Diedrich , Wolfgang Küpker
发明人： Hilde Riethmuller-Winzen , Jurgen Engel , Ricardo Felberbaum , Klaus Diedrich , Wolfgang Küpker
IPC分类号： A61K38/00
CPC分类号： A61K38/08 , A61K45/06 , A61K2300/00
摘要： The present inventions provides a method for therapeutic management of extrauterine proliferation of endometrial tissue, chronic pelvic pain and fallopian tube obstruction by short term induction treatment with an LH-RH antagonist for 4 to 12 weeks. According to another aspect of the present invention, the short term LH-RH treatment is followed by the combined or separate administration of one or more active agents selected from the group consisting of a contraceptive, preferably an oral contraceptive, a non-steroidal anti-rheumatic agent, an analgetic, an androgen other than a 17-alpha-alkyl substituted testosterone or any combinations thereof. According to a further aspect of the present invention a pharmaceutical composition comprising an LHRH antagonist and one ore more active agents selected from the group consisting of a contraceptive, preferably an oral contraceptive, a non-steroidal anti-rheumatic agent, an analgetic, an androgen other than a 17-alpha-alkyl substituted testosterone or any combinations thereof are provided.
摘要翻译： 本发明提供了一种通过LH-RH拮抗剂短期诱导治疗4至12周来治疗子宫内膜组织宫外增生，慢性盆腔疼痛和输卵管阻塞的方法。 根据本发明的另一方面，短期LH-RH治疗之后是联合或分开施用一种或多种活性剂，所述活性剂选自避孕药，优选口服避孕药，非类固醇抗生素， 风湿药，止痛剂，除17-α-烷基取代的睾酮以外的雄激素或其任何组合。 根据本发明的另一方面，包含LHRH拮抗剂和一种或多种选自避孕药，优选口服避孕药，非甾体抗风湿药，止痛剂，雄激素的活性剂的药物组合物 提供除17-α-烷基取代的睾酮或其任何组合以外的物质。
-
5.发明授权
公开(公告)号：US6106805A
公开(公告)日：2000-08-22
申请号：US961085
申请日：1997-10-30
申请人： Jurgen Engel , Klaus Diedrich , Ricardo Felberbaum
发明人： Jurgen Engel , Klaus Diedrich , Ricardo Felberbaum
CPC分类号： A61K49/0004 , A61K38/09 , Y10S514/80 , Y10S930/13
摘要： The invention relates to a diagnostic composition for improving the effectiveness of hysteroscopy, characterized in that it contains an LH-RH antagonist, in particular cetrorelix. The composition is envisaged for use prior to hysteroscopy and/or for preparation for surgery, specifically in a single dose of between 0.1 and 2 mg/kg.However, the composition can also be administered, for use prior to hysteroscopy and/or for preparation for surgery, in a multiple dose of between 0.01 and 0.5 mg/kg, preferably spread over 1-14 days. The composition is furthermore suitable for use in hysteroscopy in combination with the subsequent treatment of pathological conditions of the uterus such as myoma and endometrial hyperplasia.
摘要翻译： 本发明涉及一种用于改善宫腔镜检查有效性的诊断组合物，其特征在于其含有LH-RH拮抗剂，特别是西替瑞肽。 该组合物预期在宫腔镜检查和/或手术准备之前使用，特别是以0.1至2mg / kg的单次剂量使用。 然而，组合物也可以在宫腔镜检查之前使用和/或用于手术的准备，以0.01至0.5mg / kg的多次剂量施用，优选在1-14天内分布。 该组合物还适用于子宫镜检查，结合随后治疗子宫的病理状况，如肌瘤和子宫内膜增生。
-
公开(公告)号：US6054432A
公开(公告)日：2000-04-25
申请号：US908198
申请日：1997-08-07
IPC分类号： A61P5/24 , A61K31/495 , A61K38/04 , A61K38/09 , A61K45/00 , A61K45/06 , A61P13/08 , A61P35/00 , A61K38/00
摘要： A regime for therapeutic management of a benign prostatic hyperplasia and prostatic cancer employs Cetrorelix alone or in combination with .alpha.-reductase inhibitors or .alpha.-receptor blocking agents. The regimen reduces the volume of the prostate and avoids the side effects associated with testosterone levels being in a castration range Cetrorelix is administered at dosages between 0,5 mg/day and 20 mg/week or about 0.014 mg/kg body weight per day to 0,30 mg/kg body weight per week or at levels of about 25 to 120 mg of Cetrorelix per month or 0.376 mg kg to 1.71 mg/kg per month Cetrorelix can be administered with .alpha.-reductase inhibitors or .alpha.-receptor blocking agents.
摘要翻译： 治疗前列腺增生和前列腺癌的治疗方案单独使用西曲瑞克或与α-还原酶抑制剂或α-受体阻断剂组合使用。 该方案减少前列腺的体积，并避免与阉割水平处于阉割范围相关的副作用。西曲瑞克以0.5mg /天至20mg /周或约0.014mg / kg体重/天的剂量施用。 每周体重为0,30mg / kg或每月约25至120mg的西曲瑞克或0.376mg kg至1.71mg / kg每月Cetrorelix可以与α-还原酶抑制剂或α-受体阻断剂一起施用。
-
公开(公告)号：US5998377A
公开(公告)日：1999-12-07
申请号：US57458
申请日：1998-04-09
IPC分类号： A61P5/24 , A61K31/495 , A61K38/04 , A61K38/09 , A61K45/00 , A61K45/06 , A61P13/08 , A61P35/00 , A61K38/00 , A61K31/44
摘要： A regime for therapeutic management of a benign prostatic hyperplasia and prostatic cancer employs Cetrorelix alone or in combination with .alpha.-reductase inhibitors or .alpha.-receptor blocking agents. The regimen reduces the volume of the prostate and avoids the side effects associated with testosterone levels being in a castration range. Cetrorelix is administered at dosages between 0,5 mg/day and 20 mg/week or about 0.014 mg/kg body weight per day to 0,30 mg/kg body weight per week or at levels of about 25 to 120 mg of Cetrorelix per month or 0.376 mg/kg to 1.71 mg/kg per month. Cetrorelix can be administered with .alpha.-reductase inhibitors or .alpha.-receptor blocking agents.
摘要翻译： 治疗前列腺增生和前列腺癌的治疗方案单独使用西曲瑞克或与α-还原酶抑制剂或α-受体阻断剂组合使用。 该方案减少前列腺的体积，并避免与睾酮水平处于阉割范围相关的副作用。 西曲瑞克以0.5mg /天至20mg /周或约0.014mg / kg体重/天的剂量施用，每周至0,30mg / kg体重或约25至120mg Cetrorelix / 月或0.376mg / kg至1.71mg / kg每月。 西曲瑞克可与α-还原酶抑制剂或α-受体阻断剂一起施用。
-
公开(公告)号：US08173592B1
公开(公告)日：2012-05-08
申请号：US09523455
申请日：2000-03-10
IPC分类号： A61K38/00 , A61K38/24 , A61K38/09 , A61P15/08 , A61P15/16 , A61P15/18 , A61P5/06 , A61P5/24 , A61P5/02 , C07K14/59
CPC分类号： A61K38/24 , Y10S514/841 , A61K38/09 , A61K31/565 , A61K2300/00
摘要： A method of therapeutic management of infertility by programming of controlled ovarian stimulation and assisted reproductive procedures is disclosed containing the steps of a) suppression of premature ovulation with an LHRH-antagonist in controlled ovarian stimulation and assisted reproductive techniques with multiple follicle and oocyte development; b) programming the start of controlled ovarian stimulation by the administration to a patient of progestogen only-preparations or, alternatively, combined oral contraceptive preparations; c) exogenous stimulation of the ovarian follicle growth; d) ovulation induction with HCG, native LHRH, LHRH-agonists or recombinant LH; and e) application of assisted reproduction techniques, especially of IVF, ICSI, GIFT, ZIFT or by intrauterine insemination by sperm injection, wherein onset of the patient's menstrual cycle and of controlled ovarian stimulation are programmed in order to perform oocyte pickup and fertilization procedures during Mondays to Fridays.
摘要翻译： 公开了通过编程控制的卵巢刺激和辅助生殖过程治疗不育症的方法，其包括以下步骤：a）在受控的卵巢刺激中抑制LHRH拮抗剂的过早排卵和具有多次卵泡和卵母细胞发育的辅助生殖技术; b）通过给予仅孕激素制剂的患者或替代地联合的口服避孕制剂来编程控制卵巢刺激的开始; c）外源性刺激卵泡生长; d）用HCG，天然LHRH，LHRH激动剂或重组LH排卵诱导; 和e）应用辅助生殖技术，特别是IVF，ICSI，GIFT，ZIFT或通过精子注射子宫内授精的辅助生殖技术的应用，其中对患者的月经周期和受控的卵巢刺激的发作进行编程以在卵母细胞摄取和施肥过程中进行 周一至周五
-
公开(公告)号：US06071882A
公开(公告)日：2000-06-06
申请号：US62704
申请日：1998-04-20
IPC分类号： A61P5/24 , A61K31/495 , A61K38/04 , A61K38/09 , A61K45/00 , A61K45/06 , A61P13/08 , A61P35/00 , A61K38/00 , A61K31/18 , A61K31/50
摘要： A regime for therapeutic management of a benign prostatic hyperplasia and prostatic cancer employs Cetrorelix alone or in combination with .alpha.-reductase inhibitors or .alpha.-receptor blocking agents. The regimen reduces the volume of the prostate and avoids the side effects associated with testosterone levels being in a castration range. Cetrorelix is administered at dosages between 0.5 mg/day and 20 mg/week or about 0.014 mg/kg body weight per day to 0.30 mg/kg body weight per week or at levels of about 25 to 120 mg of Cetrorelix per month or 0.376 mg/kg to 1.71 mg/kg per month. Cetrorelix can be administered with .alpha.-reductase inhibitors or .alpha.-receptor blocking agents.
摘要翻译： 治疗前列腺增生和前列腺癌的治疗方案单独使用西曲瑞克或与α-还原酶抑制剂或α-受体阻断剂组合使用。 该方案减少前列腺的体积，并避免与睾酮水平处于阉割范围相关的副作用。 西曲瑞克以0.5mg /天至20mg /周或约0.014mg / kg体重/天的剂量施用，每周至0.30mg / kg体重或每月约25至120mg的Cetrorelix或0.376mg / kg至1.71mg / kg。 西曲瑞克可与α-还原酶抑制剂或α-受体阻断剂一起施用。
-
公开(公告)号：US20050049200A1
公开(公告)日：2005-03-03
申请号：US10661780
申请日：2003-09-15
申请人： Philippe Bouchard , Rene Frydman , Paul Devroey , Klaus Diedrich , Jurgen Engel
发明人： Philippe Bouchard , Rene Frydman , Paul Devroey , Klaus Diedrich , Jurgen Engel
摘要： A method of treating infertility disorders by 1) administering an LH-RH antagonist, preferably Cetrorelix, in amounts to selectively suppress endogenous LH but not FSH secretion and 2) inducing follicle growth by administration of exogenous gonadotropin. The selective suppression OF LH allows FSH secretion to be at natural levelS thereby not affecting individual estrogen development. The LH-RH antagonist can be given as a single or dual subcutaneous dose in the range of 1 mg to 10 mg, preferably 2 mg-6 mg. In multiple dosing-posology, LH-RH antagonist can be administered subcutaneously in an amount in the range of 0.1 to 0.5 mg of LH-RH antagonist/day. LH-RH antagonist is applied starting cycle day 1 to 10, preferably on day 4 to 8, and ovulation can be induced between day 9 and 20 of the menstruation cycle by administering rec. LH, native LH-RH, LH-RH agonist or by HCG. In addition rec. LH, native LH-RH or LH-RH agonist can be given to avoid hyperstimulation syndrome and native LH-RH or a LH-RH agonist can be administered to avoid luteal phase stimulation by neutralizing the negative effects of HCG.
摘要翻译： 一种通过以下方式治疗不育症：1）以选择性抑制内源性LH而不是FSH分泌的量施用LH-RH拮抗剂，优选Cetrorelix; 2）通过施用外源性促性腺激素诱导卵泡生长。 选择性抑制LH允许FSH分泌处于自然水平，从而不影响个体雌激素的发育。 LH-RH拮抗剂可以以1mg至10mg，优选2mg-6mg范围内的单次或双次皮下给药。 在多剂量剂量学中，LH-RH拮抗剂可以以0.1-0.5mg LH-RH拮抗剂/天的量皮下施用。 LH-RH拮抗剂在第1至10天开始循环，优选在第4至8天施用，并且可以在月经周期的第9至20天之间通过施用rec来诱导排卵。 LH，天然LH-RH，LH-RH激动剂或HCG。 另外rec。 可以给予LH，天然LH-RH或LH-RH激动剂以避免过度刺激综合征，并且可以施用天然LH-RH或LH-RH激动剂，以通过中和HCG的负面作用来避免黄体期刺激。
-
-
-
-
-
-
-
-
-
搜索结果
88 条记录 (耗时 0.022 秒)
